Novo Nordisk faces setbacks with semaglutide in Alzheimer's trials and declining growth. Read here for analyst outlook and ...

Medicare will save approximately $12 billion, or 44%, on 15 high-cost medications as a result of the second round of the ...

In a release scant on details, the Danish drugmaker said Rybelsus did improve some unspecified Alzheimer’s-related biological ...

Major stock indexes ended sharply higher Monday to begin a holiday-shortened trading week, with investors increasingly confident the Federal Reserve will cut interest rates at its December meeting.

US negotiates 71% cost reduction of Novo Nordisk’s obesity drugs for elderly Americans on government health insurance ...

The U.S. government announced it has negotiated a 71% discount on Novo Nordisk’s (NVO) Ozempic and Wegovy drugs for patients in Medicare, ...

The US government said it negotiated a 71% discount on Novo Nordisk A/S’s blockbuster Ozempic and Wegovy drugs for patients ...

Background: In January, Greystar was named as a defendant in an antitrust lawsuit filed by California Attorney General Rob ...

On a more positive note, Novo Nordisk reported positive results from a Phase 2 trial of its next highly promising GLP-1 ...

Novo Nordisk A/S is rated a Strong Buy with a huge unmet demand in obesity treatment and a low 13x P/E ratio. Learn more ...

Medicare will announce negotiated prices for 15 high-cost drugs, impacting over 67 million beneficiaries. The Inflation ...